Immuneering said new AACR pancreatic cancer data support a dual mechanism for atebimetinib, showing lower tumor volume while preserving body mass. The update adds evidence for its MAPKeeper 301 program.
published
Immuneering said new AACR pancreatic cancer data support a dual mechanism for atebimetinib, showing lower tumor volume while preserving body mass. The update adds evidence for its MAPKeeper 301 program.
Latest documented BWB result
See Billy's timestamped results and follow-through.
Review the latest gains posts, original timestamps, and proof images published by Banking With Billy.
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.